Alnylam Pharmaceut (ALNY) 63.46 $ALNY
Alnylam (ALNY) Begins Phase I/II Study on Chronic HBV Drug
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 10:34AM CDT
Alnylam Pharmaceuticals (ALNY) announced that it has started a phase I/II study on ALN-HBV for the treatment of chronic hepatitis B virus infection.
ALNY: 63.46 (+1.28), INVA: 11.77 (+0.13), PFE: 36.15 (+0.03), BMY: 75.39 (+0.11)
Alnylam Initiates Phase 1/2 Clinical Trial for ALN-HBV, an Investigational RNAi Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection
BusinessWire - Thu Jul 07, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 1/2 clinical trial with ALN-HBV, a subcutaneously administered investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The Phase 1/2 trial will be conducted initially in normal healthy volunteers, and, then, in chronic HBV patients. Initiation of this trial is based on encouraging pre-clinical data presented at the American Association for the Study of Liver Disease annual meeting in November 2015. The Company expects to report initial clinical data from patients in this study in mid-2017.
ALNY: 63.46 (+1.28)
Alnylam Stock Up on Favorable Patisiran and Revusiran Data
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 10:02AM CDT
Alnylam Pharmaceuticals' (ALNY) shares jumped 10.7% after the company reported new data from the ongoing studies on patisiran and revusiran.
ALNY: 63.46 (+1.28), INVA: 11.77 (+0.13), ANIP: 55.38 (-1.13), PFE: 36.15 (+0.03)
Alnylam Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 9.30%
Comtex SmarTrend(R) - Fri Jul 01, 2:22PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $53.56 to a high of $61.09. Yesterday, the shares gained 9.3%, which took the trading range above the 3-day high of $56.99 on volume of 861,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 63.46 (+1.28)
Alnylam to Report New Patisiran and Revusiran Results at the XV International Symposium on Amyloidosis
BusinessWire - Mon Jun 27, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that Alnylam scientists and collaborators will present preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of hereditary TTR-mediated amyloidosis (hATTR amyloidosis) at the XV International Symposium on Amyloidosis (ISA) held July 3-7, 2016 in Uppsala, Sweden.
ALNY: 63.46 (+1.28)
Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual "Helping Hands" Community Service Day
BusinessWire - Thu Jun 23, 3:30PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that over 400 of its employees participated in a company-wide community service day today to benefit ten local non-profit organizations including: Boston Nature Center, Cradles to Crayons, Emerald Necklace Conservancy, Friends of Alewife, Habitat Education Center, IMEC America, Cupboard of Kindness, Norton Conservation Land, West End House Boys and Girls Club and Windrush Farms.
ALNY: 63.46 (+1.28)
Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
PR Newswire - Fri Jun 17, 7:50AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and CytRx Corporation (NASDAQ: CYTR). Learn more about these stocks by accessing their free trade alerts at:
MACK: 5.54 (-0.08), ALNY: 63.46 (+1.28), GERN: 2.75 (+0.03), CYTR: 2.51 (+0.25)
Look for Shares of Alnylam Pharmaceuticals to Potentially Rebound after Yesterday's 1.12% Sell Off
Comtex SmarTrend(R) - Mon Jun 13, 3:59PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $61.60 to a high of $63.19. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $62.28 on volume of 605,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALNY: 63.46 (+1.28)
Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis
BusinessWire - Thu Jun 09, 7:00AM CDT
--- Company Expects to Present Initial Clinical Results in Late 2016 and to Initiate a Phase 3 Study in 2017 -
ALNY: 63.46 (+1.28)
Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
BusinessWire - Fri Jun 03, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss initial results in patients with paroxysmal nocturnal hemoglobinuria (PNH) from the ongoing Phase 1/2 study with ALN-CC5 in a webcast conference call on Saturday, June 11, 2016, at 8:30am ET. Results will be presented earlier that day in an oral presentation at the 21st Congress of the European Hematology Association (EHA) Meeting in Copenhagen, Denmark.
ALNY: 63.46 (+1.28)
After Yesterday's Rally of 7.00% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 31, 3:43PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $68.21 to a high of $72.39. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $72.16 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 63.46 (+1.28)
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
BusinessWire - Tue May 31, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
ALNY: 63.46 (+1.28)
Ionis Down, Glaxo Dumps IONIS-TTRRx Phase III Study Plans
Zacks Equity Research - Zacks Investment Research - Fri May 27, 9:45AM CDT
Ionis Pharmaceuticals' (IONS) shares touched a 52-week low after its partner Glaxo decided against starting a phase III outcome study CARDIO-TTR on IONIS-TTRRx.
ALNY: 63.46 (+1.28), GSK: 43.52 (+0.14), BMY: 75.39 (+0.11), IONS: 25.28 (-0.08)
Alnylam Pharmaceuticals (ALNY) in Focus: Stock Rises 9.9%
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:15AM CDT
Alnylam Pharmaceuticals, Inc. (ALNY) shares rose almost 10% in the last trading session.
ALNY: 63.46 (+1.28), ANIP: 55.38 (-1.13)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 1.98% Rise
Comtex SmarTrend(R) - Mon May 23, 3:47PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $54.53 to a high of $56.90. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $55.92 on volume of 256,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 63.46 (+1.28)
July 15th Options Now Available For Alnylam Pharmaceuticals (ALNY)
DividendChannel.com - Mon May 23, 10:37AM CDT
Investors in Alnylam Pharmaceuticals Inc saw new options begin trading today, for the July 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALNY options chain for the new July 15th contracts and...
ALNY: 63.46 (+1.28)
Alnylam Pharmaceuticals, Inc.'s Double-Digit "Earnings" Fall
Brian Orelli, The Motley Fool - Motley Fool - Wed May 04, 1:12PM CDT
What: Alnylam Pharmaceuticals released earnings on Monday after the bell and fell 11.6% on Tuesday. Of course, without any products on the market, the biotech's earnings don't really matter. But for the record, Alnylam recorded $7.3 million in...
ALNY: 63.46 (+1.28), MDCO: 36.19 (+1.29), ALXN: 125.30 (+0.88)
Alnylam (ALNY) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:38AM CDT
Alnylam (ALNY) reported a loss of $1.21 per share in the first quarter of 2016 on revenues of $7.3 million.
ALNY: 63.46 (+1.28), GILD: 86.25 (-0.30), SNY: 41.42 (+0.57)
Alnylam reports 1Q loss
Automated Insights - Mon May 02, 3:11PM CDT
CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Monday reported a loss of $103 million in its first quarter.
ALNY: 63.46 (+1.28)
Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta
George Budwell, The Motley Fool - Motley Fool - Mon May 02, 3:10PM CDT
Not so long ago, Alnylam Pharmaceuticals and Sarepta Therapeutics were two of the hottest clinical-stage biotech stocks because of their emphasis on developing treatments for rare diseases. However, these two former stars have fallen on hard...
ALNY: 63.46 (+1.28), SRPT: 21.37 (-1.25)
Alnylam (ALNY) Begins Phase I/II Study on Chronic HBV Drug
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 10:34AM CDT
Alnylam Pharmaceuticals (ALNY) announced that it has started a phase I/II study on ALN-HBV for the treatment of chronic hepatitis B virus infection.
ALNY: 63.46 (+1.28), INVA: 11.77 (+0.13), PFE: 36.15 (+0.03), BMY: 75.39 (+0.11)
Alnylam Initiates Phase 1/2 Clinical Trial for ALN-HBV, an Investigational RNAi Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection
BusinessWire - Thu Jul 07, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 1/2 clinical trial with ALN-HBV, a subcutaneously administered investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The Phase 1/2 trial will be conducted initially in normal healthy volunteers, and, then, in chronic HBV patients. Initiation of this trial is based on encouraging pre-clinical data presented at the American Association for the Study of Liver Disease annual meeting in November 2015. The Company expects to report initial clinical data from patients in this study in mid-2017.
ALNY: 63.46 (+1.28)
Alnylam Stock Up on Favorable Patisiran and Revusiran Data
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 10:02AM CDT
Alnylam Pharmaceuticals' (ALNY) shares jumped 10.7% after the company reported new data from the ongoing studies on patisiran and revusiran.
ALNY: 63.46 (+1.28), INVA: 11.77 (+0.13), ANIP: 55.38 (-1.13), PFE: 36.15 (+0.03)
Alnylam Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 9.30%
Comtex SmarTrend(R) - Fri Jul 01, 2:22PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $53.56 to a high of $61.09. Yesterday, the shares gained 9.3%, which took the trading range above the 3-day high of $56.99 on volume of 861,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 63.46 (+1.28)
Alnylam to Report New Patisiran and Revusiran Results at the XV International Symposium on Amyloidosis
BusinessWire - Mon Jun 27, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that Alnylam scientists and collaborators will present preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of hereditary TTR-mediated amyloidosis (hATTR amyloidosis) at the XV International Symposium on Amyloidosis (ISA) held July 3-7, 2016 in Uppsala, Sweden.
ALNY: 63.46 (+1.28)
Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual "Helping Hands" Community Service Day
BusinessWire - Thu Jun 23, 3:30PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that over 400 of its employees participated in a company-wide community service day today to benefit ten local non-profit organizations including: Boston Nature Center, Cradles to Crayons, Emerald Necklace Conservancy, Friends of Alewife, Habitat Education Center, IMEC America, Cupboard of Kindness, Norton Conservation Land, West End House Boys and Girls Club and Windrush Farms.
ALNY: 63.46 (+1.28)
Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
PR Newswire - Fri Jun 17, 7:50AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and CytRx Corporation (NASDAQ: CYTR). Learn more about these stocks by accessing their free trade alerts at:
MACK: 5.54 (-0.08), ALNY: 63.46 (+1.28), GERN: 2.75 (+0.03), CYTR: 2.51 (+0.25)
Look for Shares of Alnylam Pharmaceuticals to Potentially Rebound after Yesterday's 1.12% Sell Off
Comtex SmarTrend(R) - Mon Jun 13, 3:59PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $61.60 to a high of $63.19. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $62.28 on volume of 605,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALNY: 63.46 (+1.28)
Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis
BusinessWire - Thu Jun 09, 7:00AM CDT
--- Company Expects to Present Initial Clinical Results in Late 2016 and to Initiate a Phase 3 Study in 2017 -
ALNY: 63.46 (+1.28)
Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
BusinessWire - Fri Jun 03, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss initial results in patients with paroxysmal nocturnal hemoglobinuria (PNH) from the ongoing Phase 1/2 study with ALN-CC5 in a webcast conference call on Saturday, June 11, 2016, at 8:30am ET. Results will be presented earlier that day in an oral presentation at the 21st Congress of the European Hematology Association (EHA) Meeting in Copenhagen, Denmark.
ALNY: 63.46 (+1.28)
After Yesterday's Rally of 7.00% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 31, 3:43PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $68.21 to a high of $72.39. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $72.16 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 63.46 (+1.28)
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
BusinessWire - Tue May 31, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
ALNY: 63.46 (+1.28)
Ionis Down, Glaxo Dumps IONIS-TTRRx Phase III Study Plans
Zacks Equity Research - Zacks Investment Research - Fri May 27, 9:45AM CDT
Ionis Pharmaceuticals' (IONS) shares touched a 52-week low after its partner Glaxo decided against starting a phase III outcome study CARDIO-TTR on IONIS-TTRRx.
ALNY: 63.46 (+1.28), GSK: 43.52 (+0.14), BMY: 75.39 (+0.11), IONS: 25.28 (-0.08)
Alnylam Pharmaceuticals (ALNY) in Focus: Stock Rises 9.9%
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:15AM CDT
Alnylam Pharmaceuticals, Inc. (ALNY) shares rose almost 10% in the last trading session.
ALNY: 63.46 (+1.28), ANIP: 55.38 (-1.13)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 1.98% Rise
Comtex SmarTrend(R) - Mon May 23, 3:47PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $54.53 to a high of $56.90. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $55.92 on volume of 256,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 63.46 (+1.28)
July 15th Options Now Available For Alnylam Pharmaceuticals (ALNY)
DividendChannel.com - Mon May 23, 10:37AM CDT
Investors in Alnylam Pharmaceuticals Inc saw new options begin trading today, for the July 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALNY options chain for the new July 15th contracts and...
ALNY: 63.46 (+1.28)
Alnylam Pharmaceuticals, Inc.'s Double-Digit "Earnings" Fall
Brian Orelli, The Motley Fool - Motley Fool - Wed May 04, 1:12PM CDT
What: Alnylam Pharmaceuticals released earnings on Monday after the bell and fell 11.6% on Tuesday. Of course, without any products on the market, the biotech's earnings don't really matter. But for the record, Alnylam recorded $7.3 million in...
ALNY: 63.46 (+1.28), MDCO: 36.19 (+1.29), ALXN: 125.30 (+0.88)
Alnylam (ALNY) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:38AM CDT
Alnylam (ALNY) reported a loss of $1.21 per share in the first quarter of 2016 on revenues of $7.3 million.
ALNY: 63.46 (+1.28), GILD: 86.25 (-0.30), SNY: 41.42 (+0.57)
Alnylam reports 1Q loss
Automated Insights - Mon May 02, 3:11PM CDT
CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Monday reported a loss of $103 million in its first quarter.
ALNY: 63.46 (+1.28)
Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta
George Budwell, The Motley Fool - Motley Fool - Mon May 02, 3:10PM CDT
Not so long ago, Alnylam Pharmaceuticals and Sarepta Therapeutics were two of the hottest clinical-stage biotech stocks because of their emphasis on developing treatments for rare diseases. However, these two former stars have fallen on hard...
ALNY: 63.46 (+1.28), SRPT: 21.37 (-1.25)
